Logo image of ARCH.CA

ARCH BIOPARTNERS INC (ARCH.CA) Stock Fundamental Analysis

TSX-V:ARCH - TSX Venture Exchange - CA03938C1041 - Common Stock - Currency: CAD

1.74  0 (0%)

Fundamental Rating

2

Overall ARCH gets a fundamental rating of 2 out of 10. We evaluated ARCH against 2 industry peers in the Life Sciences Tools & Services industry. ARCH may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, ARCH is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

ARCH had negative earnings in the past year.
In the past year ARCH has reported a negative cash flow from operations.
ARCH had negative earnings in each of the past 5 years.
In the past 5 years ARCH reported 4 times negative operating cash flow.
ARCH.CA Yearly Net Income VS EBIT VS OCF VS FCFARCH.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1M -2M -3M -4M

1.2 Ratios

With a Return On Assets value of -551.08%, ARCH perfoms like the industry average, outperforming 50.00% of the companies in the same industry.
Industry RankSector Rank
ROA -551.08%
ROE N/A
ROIC N/A
ROA(3y)-309.85%
ROA(5y)-319.56%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ARCH.CA Yearly ROA, ROE, ROICARCH.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K

1.3 Margins

ARCH does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ARCH.CA Yearly Profit, Operating, Gross MarginsARCH.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -2K -4K -6K

More info and screens

1

2. Health

2.1 Basic Checks

Compared to 1 year ago, ARCH has more shares outstanding
ARCH has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, ARCH has an improved debt to assets ratio.
ARCH.CA Yearly Shares OutstandingARCH.CA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
ARCH.CA Yearly Total Debt VS Total AssetsARCH.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M 5M

2.2 Solvency

ARCH has an Altman-Z score of -85.55. This is a bad value and indicates that ARCH is not financially healthy and even has some risk of bankruptcy.
ARCH has a Altman-Z score (-85.55) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -85.55
ROIC/WACCN/A
WACCN/A
ARCH.CA Yearly LT Debt VS Equity VS FCFARCH.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2M -2M -4M

2.3 Liquidity

ARCH has a Current Ratio of 0.13. This is a bad value and indicates that ARCH is not financially healthy enough and could expect problems in meeting its short term obligations.
ARCH has a Current ratio (0.13) which is in line with its industry peers.
ARCH has a Quick Ratio of 0.13. This is a bad value and indicates that ARCH is not financially healthy enough and could expect problems in meeting its short term obligations.
The Quick ratio of ARCH (0.13) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 0.13
Quick Ratio 0.13
ARCH.CA Yearly Current Assets VS Current LiabilitesARCH.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M 5M

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 47.21% over the past year.
Looking at the last year, ARCH shows a very negative growth in Revenue. The Revenue has decreased by -105.30% in the last year.
Measured over the past years, ARCH shows a very strong growth in Revenue. The Revenue has been growing by 86.56% on average per year.
EPS 1Y (TTM)47.21%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%48.09%
Revenue 1Y (TTM)-105.3%
Revenue growth 3Y-18.27%
Revenue growth 5Y86.56%
Sales Q2Q%-100%

3.2 Future

ARCH is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.44% yearly.
ARCH is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 145.93% yearly.
EPS Next Y0%
EPS Next 2Y-52.13%
EPS Next 3Y12.44%
EPS Next 5YN/A
Revenue Next Year0%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y145.93%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
ARCH.CA Yearly Revenue VS EstimatesARCH.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2028 2029 2030 50M 100M 150M 200M 250M
ARCH.CA Yearly EPS VS EstimatesARCH.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 -0.05 -0.1 -0.15

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ARCH. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ARCH. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ARCH.CA Price Earnings VS Forward Price EarningsARCH.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ARCH.CA Per share dataARCH.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -0.05 -0.1 -0.15

4.3 Compensation for Growth

ARCH's earnings are expected to grow with 12.44% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-52.13%
EPS Next 3Y12.44%

More info and screens

0

5. Dividend

5.1 Amount

ARCH does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ARCH BIOPARTNERS INC

TSX-V:ARCH (8/8/2025, 7:00:00 PM)

1.74

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)06-03 2025-06-03
Earnings (Next)08-27 2025-08-27
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners17.92%
Ins Owner ChangeN/A
Market Cap115.03M
Analysts45.71
Price Target3.57 (105.17%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.05
EYN/A
EPS(NY)-0.16
Fwd EYN/A
FCF(TTM)-0.04
FCFYN/A
OCF(TTM)-0.04
OCFYN/A
SpS0
BVpS-0.06
TBVpS-0.06
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -551.08%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-309.85%
ROA(5y)-319.56%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover-0.44
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.13
Quick Ratio 0.13
Altman-Z -85.55
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)47.21%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%48.09%
EPS Next Y0%
EPS Next 2Y-52.13%
EPS Next 3Y12.44%
EPS Next 5YN/A
Revenue 1Y (TTM)-105.3%
Revenue growth 3Y-18.27%
Revenue growth 5Y86.56%
Sales Q2Q%-100%
Revenue Next Year0%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y145.93%
EBIT growth 1Y50.13%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-42.86%
EBIT Next 3Y-26.16%
EBIT Next 5Y82.56%
FCF growth 1Y-65.65%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-65.65%
OCF growth 3YN/A
OCF growth 5YN/A